Director, Hemostasis and Thrombosis Program
Professor of Pediatrics
Keck School of Medicine of USC
Children’s Hospital Los Angeles
Los Angeles, CA

Guy Young, MD, is the Director of the Hemostasis and Thrombosis Center and the Clinical CoagulationLaboratory at Children’s Hospital Los Angeles and a professor of pediatrics at the University of SouthernCalifornia’s Keck School of Medicine. Dr. Young has published many journal articles, abstracts, andtextbook chapters and has delivered lectures, workshops, and presentations at national andinternational meetings. He is the former chair of the Scientific and Standardization Committee on FactorVIII, Factor IX, and Rare Bleeding Disorders of the International Society on Thrombosis and Haemostasisand was awarded the National Hemophilia Foundation Physician of the Year Award in 2013.

Chief Medical and Informatics Officer
Innovative Hematology, Inc.
Indiana Hemophilia and Thrombosis Center, Inc.
Indianapolis, IN, USA

Sanjay P. Ahuja, MD, MSc, MBA, is chief medical officer at Innovative Hematology, Indiana Hemophilia and Thrombosis Center, and adjunct professor, Case Western Reserve University, Cleveland, Ohio. Dr. Ahuja is well published in the field of hemostasis and thrombosis, and his clinical and translational research program focuses on development of novel coagulation assays for bleeding disorders and complex hemostatic abnormalities in critically ill patients, early and late phase clinical trials for novel therapies in hemophilia, and gene therapy in hemophilia trials, including phase 1 studies for in vivo CRISPR/CAS9 gene insertion for hemophilia B. He is funded by the Department of Defense for development of TraumaChek and the Patient-Centered Outcomes Research Institute for outcomes research in hemophilia. He holds patents for microfluidic assays in coagulation. Dr. Ahuja is a voting member of the Blood Products Advisory committee at the US Food and Drug Administration.

Associate Professor of Pediatrics
Anne T. and Robert M. Bass Endowed Faculty Scholar in Pediatric Cancer and Blood Diseases
Director of Hematology Research
Stanford University School of Medicine
Pediatric Hematology, Oncology, Stem Cell Transplantation & Regenerative Medicine

Dr. Glaivy Batsuli is Associate Professor of Pediatrics at Stanford University and a Pediatric Hematologist with the Bass Center for Childhood Cancer and Blood Diseases at Lucile Packard Children’s Hospital. She studied Nutrition in undergrad and received her Bachelors of Science in Public Health from the University of North Carolina at Chapel Hill. She went on to receive her medical degree from the University of Pittsburgh School of Medicine in Pittsburgh, Pennsylvania. Dr. Batsuli completed her pediatrics residency and pediatric hematology & oncology fellowship at Emory University in Atlanta, Georgia where she completed her postdoctoral research training. She stayed on as faculty at Emory University until July 2023 when she joined the faculty at Stanford University as an Anne T. and Robert M. Bass Endowed Faculty Scholar in Pediatric Cancer and Blood Diseases. She continues to treat children and adolescents with classical hematologic disorders with a focus on disorders of hemostasis and thrombosis. She serves as the Director of Hematology Research and leads a basic/translational research lab program that studies mechanisms of the immune response to coagulation factor proteins.

Director, Hemophilia Treatment Center
Chief, Pediatric Hematology
Mississippi Center for Advanced Medicine (MCAM)
Louisiana Center for Advanced Medicine (LCAM)
New Orleans, LA, USA

Tammuella Chrisentery-Singleton, MD, as the chief science officer for the American Thrombosis and Hemostasis Network (ATHN), works at the strategic and policy level to inform the scientific direction of ATHN. She works across the organization to define, develop, and implement ATHN’s science and research capabilities as well as to ensure ATHN’s commitment to public health. Additionally, she cares for adult and pediatric hematology patients at the Ochsner Center for Hemostasis and Thrombosis.

Dr. Singleton’s areas of special interest include sickle cell disease, rare blood disorders, gene therapy, and musculoskeletal ultrasound in patients with hemophilia. She has authored numerous publications and led more than 60 clinical trials and research studies—including serving as the principal investigator for ATHN 16: Safety of SEVENFACT® for the Treatment of Bleeding Events in Patients with Hemophilia A or B with Inhibitors and ATHNTranscends: A Natural History Cohort Study.

Associate Professor
University of Washington School of Medicine
Division of Pediatric Hematology/Oncology & Division of Hematology and Oncology

Allison P Wheeler, MD, received her medical training at the University of Massachusetts and pediatric residency training at Baystate Medical Center. She completed her pediatric hematology/oncology and transfusion medicine fellow training at Vanderbilt University Medical Center. She worked as faculty in pediatrics and pathology at Vanderbilt from 2014-2024, at which point she transitioned to a role at University of Washington / Seattle Children’s Hospital / Washington Center for Bleeding Disorders. Allison’s clinical work has focused on patients with hemostatic and thrombotic disorders and the coagulation laboratory. In her research work Allison is currently the Scientific Director at the Washington Center for Bleeding Disorders where she has built a robust collaborative research portfolio. Her personal research interest is focused on females with heavy menstrual bleeding; in this space she is most notably working on investigation of the intrauterine device in females with heavy menstrual bleeding with and without bleeding disorders. Her academic work has also expanded to include investigation of diversity, equity, and inclusion in medicine.

Dr. Singleton’s areas of special interest include sickle cell disease, rare blood disorders, gene therapy, and musculoskeletal ultrasound in patients with hemophilia. She has authored numerous publications and led more than 60 clinical trials and research studies—including serving as the principal investigator for ATHN 16: Safety of SEVENFACT® for the Treatment of Bleeding Events in Patients with Hemophilia A or B with Inhibitors and ATHNTranscends: A Natural History Cohort Study.